{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T04:33:28Z","timestamp":1690432408865},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1678","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Asciminib (Scemblix \u2013 Novartis), an oral kinase inhibitor, has been approved by the FDA for treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with \u22652 tyrosine kinase inhibitors and for adults with Ph+ CML in CP with a T315I mutation.<\/jats:p>","DOI":"10.58347\/tml.2023.1678g","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T18:49:29Z","timestamp":1690397369000},"page":"e107-e108","source":"Crossref","is-referenced-by-count":0,"title":["Asciminib (Scemblix) for Chronic Myeloid Leukemia"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2023,6,12]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T18:49:29Z","timestamp":1690397369000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1678g"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":0,"journal-issue":{"issue":"1678","published-online":{"date-parts":[[2023,6,12]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1678g","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]}}}